SEC Filings

8-K
PERNIX THERAPEUTICS HOLDINGS, INC. filed this Form 8-K on 02/19/2019
Entire Document
 

 

33 Sales Force Impact on Silenor ® Prescribers • Pernix targets ~40% of Silenor ® TRx with its Sales force • While Pernix continues to make a positive impact on its targets, it is watching its PPD enrollments closely to ensure continued growth 43,233 55,887 16,463 49,629 53,733 16,329 – 10,000 20,000 30,000 40,000 50,000 60,000 Targets Aligned Non Targets White Space YTD 2017 YTD 2018 YOY TRx Performance by HCP Type HCP Type Healthcare Prescribing Professionals Target 3,504 Aligned Non Target (1) 25,853 White Space 7,325 Source: SHA PHAST data through October 2018. (1) Aligned Non Target represents HCPs that fall within sales territories, but on whom the field force does not actively focus educational efforts.